Outlook Therapeutics (OTLK) announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general corporate purposes. BTIG is acting as sole book-running manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics price target lowered to $8 from $10 at Guggenheim
- Biotech Alert: Searches spiking for these stocks today
- Outlook Therapeutics reports Q2 EPS (40c), consensus (55c)
- Outlook Therapeutics Approves Retention Incentive for CFO
- Outlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010